Avecho Biotechnology Limited (ASX: AVE) - Share Price
Current share price for AVE : $0.018 0.001 (5.26%)+
Avecho Biotechnology Limited (AVE), an ASX-listed company, develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.
AVE General Information +
| ASX Code | AVE |
| Website | http://www.avecho.com.au |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 68 |
| AVE Share Price | $0.018 |
| Day High | $0.020 |
| Day Low | $0.018 |
| Last Close | $0.019 |
| AVE Share Price Movement | $0.00 ( 5.26% ) |
Prices as at 16:40, 26 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Avecho Biotechnology Limited (AVE) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Final | 3¢ | 0% | 22 Sep 2010 | 21 Oct 2010 | - | - | - |
| Interim | 2¢ | 0% | 26 Feb 2010 | 24 Mar 2010 | - | - | - |
| Final | 2¢ | 0% | 30 Sep 2009 | 21 Oct 2009 | - | - | - |
See all dividends from Avecho Biotechnology Limited (AVE) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Avecho Biotechnology Limited (AVE) price-sensitive announcements
AVE - Positive interim results from Phase III insomnia program
Avecho Biotechnology Limited announced that the independent Data Monitoring Board (DMB) ha
Avecho Biotechnology Limited (AVE)
24 Jun 2026 | 8:50 AM
24 Jun 2026 | 8:50 AM
AVE - Trading Halt
Avecho Biotechnology Limited (ASX: AVE) has requested a trading halt of its securities on
Avecho Biotechnology Limited (AVE)
22 Jun 2026 | 8:31 AM
22 Jun 2026 | 8:31 AM
AVE - Receipt of Research & Development Tax Incentive
Avecho Biotechnology Limited announced the receipt of $1.98 million under the Australian G
Avecho Biotechnology Limited (AVE)
22 May 2026 | 9:41 AM
22 May 2026 | 9:41 AM
AVE - Avecho completes treatment for Phase III interim analysis
Avecho Biotechnology Limited has completed the treatment phase for the interim analysis co
Avecho Biotechnology Limited (AVE)
21 May 2026 | 10:16 AM
21 May 2026 | 10:16 AM
Avecho Biotechnology Limited (AVE) Recent ASX Announcements
AVE Financial Summary
| Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$4.42 | -$0.10 | 40.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$3.12 | -$0.10 | -28.60% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$3.07 | -$0.10 | 7.70% | 0.00 | 0.00 | 0.00% | 0.0% |
AVE Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Avecho Biotechnology Limited (AVE) | $73M | 0.4000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Clarity Pharmaceuticals Ltd (CU6) | $761M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $1,618M | -0.7857 | 0.0743 | 1.2000 | 54.8346 | 51.0400 | 23.2000 | 0.00% | 0.00% | 0.00% |
AVE Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 45.00 | 0.00 |
| Market | 0.29 | 13.30 | 1.15 | 0.66 |
| Sector | 0.42 | 26.20 | 2.41 | 2.34 |
AVE Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Gregory (Greg) Collier | Non-Executive Chairman, Non-Executive Director | 13 Apr 2015 |
| Dr Ross Murdoch | Non-Executive Director | 13 Apr 2015 |
| Ms Katherine(Kathy) Ellen Danielle Connell | Non-Executive Director | 26 Apr 2024 |
Avecho Biotechnology Limited (AVE) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 6 May 2026 | COLLIER, Gregory (Greg) | Exercise | Options | 800,000 | $0.012 | $9,600.000 |
| 6 May 2026 | COLLIER, Gregory (Greg) | Issued | Indirect Shares | 800,000 | $0.012 | $9,600.000 |
| 22 Nov 2023 | MCNAMARA, Matthew | Issued | Indirect Shares | 1,666,666 | $0.006 | $9,999.996 |
See all changes in directors' interest & trades for Avecho Biotechnology Limited (AVE) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
AVE Management
| Name | Position |
|---|---|
| Paul Gavin | Chief Executive Officer |
| Roksan Libinaki | Chief Operating Officer |
| Naomi Lawrie | Company Secretary |
AVE Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Avecho Biotechnology Limited (AVE). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 349,133,188 (9.50%) | Mark Gregory KERR |
AVE Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Annual) |
| 26 February 2027 | Report (Prelim) |
| 27 August 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
